Primary culture of endometrial mesenchymal stem cells derived from ectopic lesions of patients with adenomyosis

Xinjun Wei, Xiaoxia Wei, Aiyun Xu, Andi Xu, Shuyu Xia, S. Xia, Jindan Wang, Jia‐Yi Wang, Yingying Qiu, Guiping Wan, Jian Cao, Zhihui Wang, Tao Gui
Archives of gynecology and obstetrics · 2024 · vol. 310(6) , pp. 3239–3253 · doi:10.1007/s00404-024-07854-y · PMID:39623118 · W4404908971
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

The enzymatic explant method, enhanced with A83-01, efficiently isolates and expands adenomyotic lesion-derived endometrial mesenchymal stem cells with increased proliferation and differentiation potential.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This study aimed to develop an efficient in vitro protocol to isolate and expand endometrial mesenchymal stem cells derived from adenomyotic ectopic lesions (A-eMSCs) from patients with adenomyosis, comparing enzymatic, explant, and enzymatic-explant isolation approaches. Using the enzymatic-explant method, the authors reported improved cell morphology, faster confluence, and higher SUSD2 enrichment, with isolated cells showing significantly greater proliferation and differentiation potential in vitro than cells obtained by the other methods. They further tested the TGF-β type I receptor inhibitor A83-01 and found it reduced confluence time during isolation, increased A-eMSC enrichment, and enhanced proliferation while maintaining differentiation potential during expansion, with the authors emphasizing the protocol’s robustness and cost-effectiveness as a foundation for further pathogenesis and treatment work. This paper is centrally about endometriosis and adenomyosis — it specifically focuses on isolating and expanding adenomyosis-derived endometrial mesenchymal stem cells and modulating them with a TGF-βR1 inhibitor.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (58)

SciLite annotations

chemicals 1
ncgc00381123-01

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-04T00:32:11.098073+00:00
scilite
last seen: 2026-05-18T04:26:01.642840+00:00
License: CC0 · commercial use OK